1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group
This psychological boost can translate into feeling more energetic and engaged in daily activities
Read that sentence again with the timeline in mind
Potential Side Effects and Considerations Both Semaglutide and Tirzepatide are generally well-tolerated, but like any medication, they come with potential side effects
It can sometimes be considered for people with a BMI of 3034.9 if they have certain serious health conditions, but this is less common
NHS Tier 3 weight management services provide intensive behavioural interventions that address the complex factors contributing to obesity
